IN THIS ISSUE

Jan Greene

When Alexander Graham Bell phoned it in, so to speak, who could have predicted that it would eventually lead to IBM’s Watson Health tackling medication adherence with state-of-the-art analytics?

Joseph Burns

Information overload from a flood of new diagnostics forces insurers to ramp up prior authorization and utilization review.

Thomas Reinke

Michael Sherman, MD
Harvard Pilgrim

Manufacturers are starting to offer significant rebates in exchange for preferred status on an insurer’s formulary.

Joseph Burns
California and other states have put monthly caps on out-of-pocket medication expenses. But the caps might shift some costs over to premiums.
Q&A
Interview by Peter Wehrwein

Steven Pearson, MD, ICER

The Value of Drugs: It Is Not About the Money!
Original Research
Ana D. Vega, BS
Paul P. Meola, BS
Julio Ramon Barcelo Jr.
Legislation & Regulation
Richard Mark Kirkner

Katie Holcomb
Milliman

It seems like Godot may arrive sooner. Seven years after the biosimilar law was enacted, stakeholders are losing patience with the FDA.
Ed Silverman

A Harvard Law School group is among those that have taken action.

Viewpoint
Richard G. Stefanacci, DO
Scott Guerin, PhD

Managed care organizations need to work on several fronts if they are to improve patient adherence. Limiting out-of-pocket costs is one place to start.

Tomorrow’s Medicine
Thomas Morrow, MD

Sarepta’s eteplirsen functions like an RNA patch so functioning dystrophin gets made. Other drugs like it may be used to treat Ebola and other viral infections.

Biologics in Development
Katherine T. Adams
Cancer Watch
Peter Wehrwein
Organized oncology isn’t ready to give up on ASP+6 payment for Medicare Part B drugs. But experimentation with value-based pricing has some supporters.